An interventional study of AI-assisted remote monitoring of flap perfusion abnormalities after first-stage auricular reconstruction in Congenital Microtia, sponsored by Jing Xu. Not yet recruiting at 1 site in China. Open to participants aged 6 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by Jing Xu · Not applicable, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of this study is to develop a convolutional neural network-based image recognition model to identify flap perfusion abnormalities after first-stage auricular reconstruction in patients with congenital microtia. In addition, the study seeks to evaluate the real-world performance of this model when applied to clinical flap monitoring.
The main questions addressed are:
The study is divided into two phases.
Patients admitted between July 2027 and December 2027 who meet the inclusion criteria will receive conventional clinical flap monitoring and routine follow-up and will comprise the control group.
Patients admitted between January 2028 and June 2028 who meet the inclusion criteria will receive flap monitoring using the convolutional neural network-based image recognition module in addition to standard clinical management and follow-up and will comprise the study group.
Investigators will compare postoperative complication rates, the accuracy of detecting flap perfusion abnormalities, and satisfaction among patients and healthcare providers between the two groups.
Participants will:
33 studies on the registry are indexed under Congenital Microtia; 10 are open to participants now.
This study's planned enrollment of 232 is above the median of 34 across 23 interventional studies indexed under Congenital Microtia.
Browse Congenital Microtia studies →Jing Xu is the lead sponsor of 2 studies on the registry; 2 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with congenital microtia will undergo first-stage auricular reconstruction with standard flap assessment and routine follow-up, without AI-based remote flap image monitoring.
Participants will undergo first-stage auricular reconstruction and receive AI-assisted remote flap monitoring postoperatively, with scheduled image acquisition and flap assessment conducted according to the study protocol.
Behavioral: AI-assisted remote monitoring of flap perfusion abnormalities after first-stage auricular reconstruction
In addition to routine outpatient follow-up, an AI image recognition-based remote intelligent monitoring system led by specialist nurses will be implemented. After discharge, patients will receive daily prompts to upload photographs of the reconstructed ear. The AI system will analyse images in real time: if classified as normal, it will provide standard care recommendations; if classified as abnormal, it will automatically alert the clinical team. Specialist nurses will manually review abnormal images and, as appropriate, request repeat imaging, intensify home care and increase monitoring frequency, or report to the supervising physician and instruct the patient to return to the hospital for further management.
Complication rate
Complications will be identified and recorded based on outpatient review notes and follow-up records. The complication rate will be calculated as: Complication rate = (number of patients with complications after first-stage auricular reconstruction / total number of patients) × 100%. The following common postoperative complications after first-stage auricular reconstruction will be included: hematoma requiring re-hemostasis, infection, flap necrosis, cartilage exposure, and deformation of the auricular framework.
Time frame: Assessed 3 months postoperatively
Patient satisfaction
Patient satisfaction will be assessed using a self-designed satisfaction questionnaire comprising 15 items divided into five domains: consultation process and environment (3 items), quality of medical and nursing services (3 items), attitude of medical and nursing staff (3 items), health education (3 items), and use of the case management platform (3 items). Each item will be rated on a 3-point Likert scale from "dissatisfied" to "satisfied," scored 1-3, yielding a total score range of 15-45. The satisfaction score will be calculated as the sum of all item scores, with higher scores indicating greater patient satisfaction.
Time frame: Assessed 3 months postoperatively
System complication detection rate
The system complication detection rate will be calculated as: System complication detection rate = (number of cases classified as abnormal by the system and clinically confirmed to have auricular reconstruction complications / total number of cases classified as abnormal by the system) × 100%.
Time frame: Assessed at 3 months postoperatively
Plan to share: No — Individual participant data will not be shared with external researchers due to patient privacy protection and institutional data policy. Aggregated study results will be reported in publications.
Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jing Xu